The delayed PDUFA date and lack of labeling talks with the FDA presaged unhappy news for Amag Pharmaceuticals Inc. regarding its supplemental new drug application (sNDA) for intravenous Feraheme (ferumoxytol), and a complete response letter (CRL) came next.